The absence of species-specific antivenoms is both a public-health and a conservation problem. Critically analyse in the Indian context.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →Antivenom works reliably only against the venoms used to make it. India's polyvalent antivenom is made from the venom of the mainland 'Big Four' snakes. For island endemics such as the Andaman cobra (Naja sagittifera), no commercially available antivenom exists [1]. This one gap harms both patients and the species.
Public-health dimension
- Treatment mismatch: a Port Blair hospital may stock antivenom yet have none raised against this highly venomous, venom-spitting cobra [1].
- Policy blind spot: NAPSE (2024) prioritises better access to treatment [2], but access to an unmatched vial does not help island patients.
- Invisible burden: official data record about 2,000 deaths a year (CBHI, 2016–20) [2] and do not note the biting species, so demand for an island antivenom cannot be shown.
Conservation dimension
- Fear-killing: a dangerous bite with no matching cure makes people kill the snake on sight [1].
- Genetic fragility: each killing shrinks an isolated gene pool already prone to inbreeding, which causes birth defects and poor fertility [1].
- No rescue option: being endemic, it cannot be restocked by translocation; deforestation and farm expansion add pressure [1].
- Neglect: a century after Frank Wall described it (1913), it remains barely studied [1].
Critical assessment
- Against: most snakebite deaths occur on the mainland; a product for a tiny market is commercially unviable, and the same funds may save more lives elsewhere.
- But: lost endemic biodiversity cannot be restored. Cheaper first steps exist, such as lab-testing existing antivenoms against island venom before any manufacture.
- Awareness alone [1] is weak when fear is rational; credible treatment makes "don't kill" messages believable.
Way forward
- Bring island endemics into NAPSE's One Health framework [2]; fund venom-neutralisation studies in public labs.
- Island hospitals should record the biting species in every case.
- MoEFCC should confirm the species' legal and threat status and fund population surveys.
- Pair outreach with first-aid and rapid-referral training.
The antivenom gap is thus one problem with two faces: untreated bites breed fear, and fear erodes a fragile species. A research-first, One Health approach, aligned with WHO's goal of halving snakebite deaths and disability by 2030 [3], can protect island lives and fulfil Article 48A's mandate to safeguard wildlife.
Sources
- 1India's sole island-dwelling cobra faces conservation challenges, *The Hindu* (22 Nov 2026)no commercial antivenom; spitting venom; fear-killing; inbreeding risk; endemism and no translocation; deforestation and farm expansion; Frank Wall's 1913 description; community awareness
- 2PIB: Union Health Ministry launches National Action Plan for Prevention and Control of Snakebite Envenoming in India (12 Mar 2024)NAPSE's One Health approach and access-to-treatment strategy; CBHI figure of about 2,000 deaths a year (2016–20)
- 3WHO, *Snakebite Envenoming: A Strategy for Prevention and Control* (2019)global goal of halving snakebite deaths and disability by 2030
Practice
6 questions on this article
Check the answer for each question, or reveal all at once.